VANCOUVER, BC, Jan. 26, 2022 /CNW/ - NeutriSci International
Inc. ("NeutriSci" or the "Company") (TSXV: NU) (OTCQB:
NRXCF) (FSE: 1N9), an innovative technology company developing
products, licensing IP and technology for B2B partnerships and the
nutraceutical industry, announces that, it in order to direct
capital to other activities, will voluntarily delist its common
shares from trading on the OTCQB. The delisting will be
effective prior to the opening of the markets on February 1, 2022.
The Company expects its common shares may thereafter be eligible
for quotation on the Pink tier of OTC Markets Group if market
makers commit to making a market in the Company's shares. The
Company can provide no assurance that trading in its common shares
will continue on the OTC Markets Group or otherwise. For quotes or
additional information on the OTC Pink market, please
visit http://www.otcmarkets.com.
The Company's shares will continue to trade on the TSXV, and the
FSE.
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production, and
formulation of nutraceutical products. Established in 2009,
NeutriSci's is building sustainable sales models with Convenience,
Chain Drug, and Mass Market and Supermarket retailers for its
products offering co-branding as well as private label
opportunities and contract manufacturing services. For more
information, please visit: www.neutrisci.com.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
Tel: (403) 264-6320
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accept responsibility for the adequacy or accuracy of
this release.
This news release may include forward-looking statements that
are subject to risks and uncertainties. All statements within,
other than statements of historical fact, are to be considered
forward-looking. Although the Company believes the
expectations expressed in such forward-looking statements are based
on reasonable assumptions, such statements are not guarantees of
future performance and actual results or developments may differ
materially from those in forward-looking statements. Factors
that could cause actual results to differ materially from those in
forward-looking statements include market prices, continued
availability of capital and financing, and general economic, market
or business conditions. There can be no assurances that such
statements will prove accurate and, therefore, readers are advised
to rely on their own evaluation of such uncertainties. We do
not assume any obligation to update any forward-looking statements
except as required under the applicable laws.
Statements in this press release have not been evaluated by
the Food and Drug Administration. Products or ingredients are
not intended to diagnose, treat, cure, or prevent any
disease.
SOURCE NeutriSci International Inc.